Dual targeting of BCMA and GPRC5D with the trispecific antibody ramantamig addresses antigenic heterogeneity in myeloma - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Ramantamig’s trispecific targeting of BCMA and GPRC5D may overcome antigen heterogeneity in multiple myeloma

  • By

  • Chloe O'Neill

  • Marloes E. C. Broekmans

  • Charlotte L. B. M. Korst

  • Maria Krevvata

  • Giada Dal Collo

  • Richard W. Groen

  • Bing Li

  • Serena R. Baglio

  • Ulrike Philippar

  • Kodandaram Pillarisetti

  • Sonja Zweegman

  • Deeksha Vishwamitra

  • Tuna Mutis

  • Niels W. C. J. van de Donk

  • October 7, 2026

Share

Original Source(s)

Dual targeting of BCMA and GPRC5D with the trispecific antibody ramantamig addresses antigenic heterogeneity in myeloma

  • by Chloe O'Neill, Marloes E. C. Broekmans, Charlotte L. B. M. Korst, Maria Krevvata, Giada Dal Collo, Richard W. Groen, Bing Li, Serena R. Baglio, Ulrike Philippar, Kodandaram Pillarisetti, Sonja Zweegman, Deeksha Vishwamitra, Tuna Mutis, Niels W. C. J. van de Donk

  • October 7, 2026

Related Content

Survival Outcomes With Lu-177 PSMA by Treatment Line and Taxane Sequencing in Prostate Cancer

Short-term outcomes of a novel anti-reflux biologic flap technique versus double flap technique after laparoscopic proximal gastrectomy: a retrospective cohort study

Three Targets, One CAR T Therapy

First-in-human study demonstrates the potential of rapidly manufactured trispecific CAR T cells to deliver durable remissions in B-cell lymphoma

  • October 19, 2026

  • 4 min